Beta Bionics announced today that it launched the integration of the iLet bionic pancreas with the Abbott (NYSE:ABT) ...

Automated insulin delivery (AID) systems reduce diabetes distress and fear of hypoglycemia, improve quality of life, and increase awareness about hypoglycemia in adults, children, and adolescents ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

Insulet ( (PODD) ) has released its Q3 earnings. Here is a breakdown of the information Insulet presented to its investors. Insulet ...

Continuous Glucose Monitoring (CGM) is transforming diabetes care in India, where the disease has reached alarming rates. Continuous Glucose Monitorin ...

Insulet (Nasdaq:PODD) shares ticked up today on third-quarter results that came in well ahead of the consensus forecast.

The Luna system was developed as a wearable insulin pump and alternative to insulin pen to automate the insulin delivery ...

real-time approach in contrast to conventional insulin delivery systems, which need patients to enter data and modify their own dosages manually. The system improves its predictions over time to ...

Revenue grew 26% to $543.9 million, ahead of the $519.5 that analysts forecast. Chief Executive Jim Hollingshead said the company's Omnipod 5 automated insulin delivery system -- which was cleared by ...

Revolutionary glucose-responsive insulin NNC2215 offers hope for diabetics, managing blood sugar levels without hypoglycemia ...